Welkins, LLC

Welkins, LLC specializes in systems for thermal management in critical care environments. Their primary products include circulating-fluid localized thermal therapy devices, which deliver targeted cooling to specific areas of the body, and external temperature regulation control units designed exclusively for cooling patient core temperatures. These devices are used in emergency medicine and intensive care units to help manage hyperthermia or fever.

Welkins, LLC is headquartered in the United States. The company’s location influences its regulatory framework, as it operates under FDA guidelines. Since its devices are classified as Class II, they undergo a premarket notification (510(k)) process to demonstrate substantial equivalence to a predicate device before entering the market. The FDA’s jurisdiction ensures compliance with U.S. medical device regulations.

Welkins, LLC’s devices are included in the FDA’s 510(k) premarket submission database and the Unique Device Identifier (UDI) system. These registries track authorized medical devices in the U.S. market, ensuring transparency and traceability for healthcare providers and regulators. The 510(k) database verifies compliance with FDA requirements, while the UDI system standardizes device identification for better safety monitoring.

Welkins, LLC’s products fall under FDA Class II classification, which applies to devices posing moderate risk to patients. This classification requires manufacturers to submit a 510(k) premarket notification to demonstrate that their device is substantially equivalent to a legally marketed predicate device. Class II devices undergo additional controls, such as performance standards or post-market surveillance, to ensure safety and effectiveness without the need for rigorous clinical trials like Class III devices.